Anterogen Overview

  • Founded
  • 2000

Founded
  • Status
  • Public

  • Employees
  • 41

Employees
  • Stock Symbol
  • 065660

Stock Symbol
  • Share Price
  • $17.03

  • (As of Friday Closing)

Anterogen General Information

Description

Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
KRX
Primary Office
  • 345-30 Gasan-dong
  • Geumcheon-gu
  • Seoul, 08589
  • South Korea
+82 00-0000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Anterogen Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$17.03 $16.53 $15.13 - $88.78 $161M 9.7M 62.1K -$0.02

Anterogen Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 182,744 470,506 483,866 284,514
Revenue 7,110 7,090 3,516 3,557
EBITDA 394 1,026 (3,059) (2,796)
Net Income (297) (484) (3,705) (3,473)
Total Assets 128,114 114,873 86,353 73,030
Total Debt 9,439 9,891 8,482 7,206
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Anterogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Anterogen‘s full profile, request access.

Request a free trial

Anterogen Patents

Anterogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2020033377-A Mesenchymal stem cell-hydrogel-biodegradability or mesenchymal stem cell-hydrogel-non-degradable support composition for alleviating or improving epidermolysis bullosa Pending 12-Apr-2016 0000000000
EP-3290028-A1 Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-nondegradable support composition for alleviating or remedying epidermolysis bullosa Pending 12-Apr-2016 00000000000
JP-2018515444-A Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-non-degradable support composition for alleviating or improving bullous epidermis Granted 12-Apr-2016 00000000000 0
EP-3290028-A4 Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-nondegradable support composition for alleviating or remedying epidermolysis bullosa Pending 12-Apr-2016 0000000000 0
JP-6810706-B2 Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-non-degradable support composition for alleviating or ameliorating bullous epidermal ablation Active 12-Apr-2016 A61L27/3813
To view Anterogen’s complete patent history, request access »

Anterogen Executive Team (3)

Name Title Board Seat Contact Info
Sung-Koo Lee Co-Chief Executive Officer & Board Member
Lee Seong-gu Co-Chief Executive Officer
Ike Wan Lee Ph.D Chief Scientific Officer & Founder
To view Anterogen’s complete executive team members history, request access »

Anterogen Board Members (2)

Name Representing Role Since
Mi-hyung Kim Anterogen Board Member 000 0000
Sung-Koo Lee Anterogen Co-Chief Executive Officer & Board Member 000 0000
To view Anterogen’s complete board members history, request access »

Anterogen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Anterogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Anterogen‘s full profile, request access.

Request a free trial